{"entity":{"id":"nct04489771","kind":"trial","name":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","aka":[],"tldr":"A phase 2 trial of Belzutifan in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) is a phase 2 interventional study registered as NCT04489771 by Merck Sharp & Dohme LLC, with 154 participants enrolled, started 2020-09-13 and due to reach its primary completion in 2023-02-10. Interventions recorded: Belzutifan. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04489771","url":"https://clinicaltrials.gov/study/NCT04489771"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["belzutifan"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04489771","phase":"2","setting":"Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma","sponsor":"Merck Sharp & Dohme LLC","started":"2020-09-13","startedType":"actual","yearReported":2024,"enrolled":154,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","primary":true,"unit":"%","arms":[{"name":"Belzutifan 200 mg","n":78,"value":23.1,"note":"95% CI 14.3 to 34.0; Figures from the ClinicalTrials.gov results section (first posted 2024-02-28), not from a publication"},{"name":"Belzutifan 120 mg","n":76,"value":23.7,"note":"95% CI 14.7 to 34.8"}],"p":"0.5312","source":"https://clinicaltrials.gov/study/NCT04489771?tab=results"}]},"route":"/trials/nct04489771/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}